Nutritional formulation for promoting catch-up growth

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The Nestec S.A. patent solves the following problem:

It has been recognized for many years that the growth pattern of young mammals who suffer stress as a result of physical illness or injury or psychological trauma is often interrupted. If the young mammal a swift recovery and adequate nutrition is, then it can compensate for the growth that occurred during the period of stress and this sudden rapid growth known arrest growth. However, this does not always happen. For example, the young mammal may suffer from anorexia both during the illness or injury and his immediate human food and may therefore be limited. In severe cases these animals never reach the physical size that it would have reached a pressure not suffered.

Our analysis of this patent is as follows:

Nestec S.A.’s patent US 9144250 B2 deals with Nutritional formulation for promoting catch-up growth.
This invention relates to a nutritional formulation comprising a N3 long-chain polyunsaturated fatty acid (LC-PUFA), a prebiotic fiber and a probiotic bacterial strain mixture act in a synergistic way promote footage growth in young mammals whose growth has to be wrong because the young mammal has been subjected to physical or mental stress.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Devices and methods for reducing vehicle drag

Use PowerPatent’s Online Patent Filing Service to get quick patent protection for your great idea.

The Smarttruck Systems, Llc patent solves the following problem:

An ongoing effort to reduce the drag in vehicular structures is of great importance as the fuel economy will be a greater consideration in vehicular design. As the drag of a car increases, the amount of fuel needed to move vehicles also increased because of greater energy required to overcome drag. For example, it states that for a vehicle traveling at 70 mph, 65% of the total fuel consumption of the engine of the car used to overcome drag. Therefore, even a small reduction in drag experienced by a vehicle traveling at a speed of course would result in a significant improvement in fuel economy.

Our analysis of this patent is as follows:

Smarttruck Systems, Llc’s patent US 9056636 B2 deals with Devices and methods for reducing vehicle drag.
In some embodiments of the present invention, a vehicle trailer is described which includes a shelf component that extends from the side wall of the trailer and that describes a sloped surface.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Amino-pyridine-containing spleen tyrosine kinase (SYK) inhibitors

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Merck Sharp & Dohme Corp. patent solves the following problem:

Spleen Tyrosine Kinase (SYK) is a protein tyrosine kinase described as a key mediator of immunoreceptor signaling a host of inflammatory cells including mast cells, B-cells, macrophages and neutrophils. These immunoreceptors, including Fc receptor and the B-cell receptor, is important for allergic diseases, and antibody-mediated autoimmune diseases and thus pharmacologically interfering SYK conceivably treat these diseases.

Our analysis of this patent is as follows:

Merck Sharp & Dohme Corp.’s patent US 8796310 B2 deals with Amino-pyridine-containing spleen tyrosine kinase (SYK) inhibitors.
invention provides certain amino-pyridine-containing compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, P3, R4, R5, R6, R7, R8, R9, and n are as described here. invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated spleen tyrosine kinase (SYK) kinase.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

7-(1H-pyrazol-4-yl)-1,6-naphthyridine compounds as Syk inhibitors

Patent Registration – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Glaxo Group Limited patent solves the following problem:

Our analysis of this patent is as follows:

Glaxo Group Limited’s patent US 8633319 B2 deals with 7-(1H-pyrazol-4-yl)-1,6-naphthyridine compounds as Syk inhibitors.
The present invention relates to a compound of formula (I): or a salt thereof; which is an inhibitor of spleen tyrosine kinase (SYK) and therefore potential use in the treatment of diseases resulting from inappropriate activation of mast and / or basophil cells, macrophages, and B-cells and related inflammatory response and tissue damage, for example, inflammatory disease, and / or allergic disorders, and cancer therapy, especially heme malignancies, chronic spontaneous urticaria and autoimmune conditions.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Drag reducing apparatus for a vehicle

Patent Registration – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Aerodynamic Trailer Systems, Llc patent solves the following problem:

The present invention is a division of US application Ser. No. 12 / 594,662 at December 23, 2009, which in turn claims priority to US Provisional Patent Application Ser. No. 60 / 907,554 and May 5, 2007, and PCT / US08 / 059382 and May 4, 2008, incorporated here by reference.

Our analysis of this patent is as follows:

Aerodynamic Trailer Systems, Llc’s patent US 8622462 B2 deals with Drag reducing apparatus for a vehicle.
exposure consisted of a pair of inflatable substantially inelastic lobes. A claim can be mounted on each of the rear trailer door with a standard tractor-trailer unit. Each lobe can be inflated or deployed to give a flying substantially planar contour extending rearwardly back end of the car. The flying form lobes with strong and substantially planar outer surface for the wind up will be done in a series of internal rope and flag set extending substantially horizontally and vertically in a forest from a chasing side to the other side of each sheet. When the lobes shrink, the trailer door can be opened and decided on the side of the trailer in a conventional manner.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Immunemodulating oligosaccharides

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The N.V. Nutricia patent solves the following problem:

The immune system has different possible ways to react to an antigen. A decisive step for the type of immune response is the stimulation of different T-cell subpopulations. So called Th1 cells typically produce cytokines, which stimulate a cellular immune response (IFN-, IL-12, IL-2). In contrast, Th2 cells typically produce IL-4, IL-5 and IL-0. These cytokines boost an IgE-mediated allergic reaction and inflammation and also thought to be involved in recruitment, growth, inequality, maintenance and survival of eosinophils (ie, leukocytes that accept an eosin stain), which can be leading to eosinophilia. Eosinophilia is a hallmark of many Th2 mediated diseases, such as asthma, allergies, and atopic dermatitis. Th1- and Th2-related cytokines act antagonistically and the Th1 / Th2 responses are under normal physiological circumstances in a well-controlled balance. Neither the Th1 nor the Th2 response prevails. If disbalance, the rule of one of Th1 or Th2 immune responses play a role in or is responsible for several pathological conditions.

Our analysis of this patent is as follows:

N.V. Nutricia’s patent US 8557794 B2 deals with Immunemodulating oligosaccharides.
The present invention relates to a method for enhancing the immune system and the treatment and / or prevention of related immune system disorder in a mammal, particularly newborns, said method comprising the administration of acid oligosaccharide and neutral oligosaccharide. Food composition suitable for use in the methods above is also given.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Determining the capability of a test compound to affect solid tumor stem cells

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with PowerPatent’s Utility, Provisional or Design Patent Filing Software

The The Regents Of The University Of Michigan, , Oncomed Pharmaceuticals, Inc. patent solves the following problem:

Cancer remains the number two cause of death in this country, resulting in more than 500,000 deaths each year. Despite progress in detection and treatment, cancer mortality remains high. Despite remarkable progress in understanding the molecular basis of cancer, this knowledge has not yet translated into effective therapeutic strategies.

Our analysis of this patent is as follows:

The Regents Of The University Of Michigan, , Oncomed Pharmaceuticals, Inc.’s patent US 8420885 B2 deals with Determining the capability of a test compound to affect solid tumor stem cells.
A small percentage of cells in a firm with strong tumor properties of stem cells. These strong tumor stem cells give rise to two more tumor stem cells and the majority of tumor cells that have lost the capacity for growth and the ability to give rise to new tumors. Therefore, strong tumor heterogeneity appeared before the tumor cell line arising from a strong tumor stem cells. A xenograft model in which we can build in tumors from primary tumors by injection of tumor cells in mammary England severely immunodeficient mice. These xenograft assay allows us to do the biological and molecular assays virtue clonogenic strong tumor stem cells. We also found evidence that strongly implicates the notch road, especially to notch 4, as playing a central pathway of carcinogenesis.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.